Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
GH Research management to meet virtually with Stifel » 04:55
06/24/22
06/24
04:55
06/24/22
04:55
GHRS

GH Research

$10.50 /

+0.53 (+5.32%)

Virtual Meeting to be…

Virtual Meeting to be held on June 24 hosted by Stifel.

ShowHide Related Items >><<
GHRS GH Research
$10.50 /

+0.53 (+5.32%)

GHRS GH Research
$10.50 /

+0.53 (+5.32%)

06/15/22 Roth Capital
GH Research initiated with a Buy at Roth Capital
04/13/22 Canaccord
GH Research price target lowered to $41 from $45 at Canaccord
12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
GHRS GH Research
$10.50 /

+0.53 (+5.32%)

  • 25
    Jun
Conference/Events
GH Research management to meet virtually with Stifel » 17:08
06/21/22
06/21
17:08
06/21/22
17:08
GHRS

GH Research

$10.79 /

+0.015 (+0.14%)

Virtual Meeting to be…

Virtual Meeting to be held on June 24 hosted by Stifel.

ShowHide Related Items >><<
GHRS GH Research
$10.79 /

+0.015 (+0.14%)

GHRS GH Research
$10.79 /

+0.015 (+0.14%)

06/15/22 Roth Capital
GH Research initiated with a Buy at Roth Capital
04/13/22 Canaccord
GH Research price target lowered to $41 from $45 at Canaccord
12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
GHRS GH Research
$10.79 /

+0.015 (+0.14%)

  • 25
    Jun
Initiation
GH Research initiated with a Buy at Roth Capital » 17:08
06/15/22
06/15
17:08
06/15/22
17:08
GHRS

GH Research

$9.85 /

-0.535 (-5.15%)

Roth Capital initiated…

Roth Capital initiated coverage of GH Research with a Buy rating and $66 price target. The analyst noted that GH Research is "amongst the first to develop medicines to precipitate remissions in hours in Treatment Resistant Depression," or TRD, where currently available treatments provide benefits in weeks or months.

ShowHide Related Items >><<
GHRS GH Research
$9.85 /

-0.535 (-5.15%)

GHRS GH Research
$9.85 /

-0.535 (-5.15%)

04/13/22 Canaccord
GH Research price target lowered to $41 from $45 at Canaccord
12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
GHRS GH Research
$9.85 /

-0.535 (-5.15%)

  • 25
    Jun
Over a month ago
Hot Stocks
GH Research expects cash to fund operations into 2025 » 07:08
05/18/22
05/18
07:08
05/18/22
07:08
GHRS

GH Research

$11.00 /

+0.895 (+8.86%)

The company said,…

The company said, "Cash was $270.8 million as of March 31, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing cash will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2025."

ShowHide Related Items >><<
GHRS GH Research
$11.00 /

+0.895 (+8.86%)

GHRS GH Research
$11.00 /

+0.895 (+8.86%)

04/13/22 Canaccord
GH Research price target lowered to $41 from $45 at Canaccord
12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
GHRS GH Research
$11.00 /

+0.895 (+8.86%)

  • 25
    Jun
GHRS GH Research
$11.00 /

+0.895 (+8.86%)

Earnings
GH Research reports Q1 EPS (11.1c), consensus (16c)  07:08
05/18/22
05/18
07:08
05/18/22
07:08
GHRS

GH Research

$11.00 /

+0.895 (+8.86%)

 
ShowHide Related Items >><<
GHRS GH Research
$11.00 /

+0.895 (+8.86%)

GHRS GH Research
$11.00 /

+0.895 (+8.86%)

04/13/22 Canaccord
GH Research price target lowered to $41 from $45 at Canaccord
12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
GHRS GH Research
$11.00 /

+0.895 (+8.86%)

  • 25
    Jun
GHRS GH Research
$11.00 /

+0.895 (+8.86%)

Recommendations
GH Research price target lowered to $41 from $45 at Canaccord » 07:45
04/13/22
04/13
07:45
04/13/22
07:45
GHRS

GH Research

$19.59 /

+0.6 (+3.16%)

Canaccord analyst Sumant…

Canaccord analyst Sumant Kulkarni lowered the firm's price target on GH Research to $41 from $45 and keeps a Buy rating on the shares. The analyst said his thesis remains unhanged; he believes recent Phase 2 data were robust, and that shares remain significantly undervalued if GH001 turns out to be an ultra-rapid treatment for TRD.

ShowHide Related Items >><<
GHRS GH Research
$19.59 /

+0.6 (+3.16%)

GHRS GH Research
$19.59 /

+0.6 (+3.16%)

12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
07/20/21 Canaccord
GH Research initiated with a Buy at Canaccord
GHRS GH Research
$19.59 /

+0.6 (+3.16%)

  • 25
    Jun
GHRS GH Research
$19.59 /

+0.6 (+3.16%)

Over a quarter ago
Hot Stocks
GH Research expects cash to fund operating expenses into 2025 » 07:11
03/28/22
03/28
07:11
03/28/22
07:11
GHRS

GH Research

$16.85 /

-0.01 (-0.06%)

Cash was approximately…

Cash was approximately $273.8 million as of February 28, 2022, and we believe that our existing cash will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2025.

ShowHide Related Items >><<
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

GHRS GH Research
$16.85 /

-0.01 (-0.06%)

12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
07/20/21 Canaccord
GH Research initiated with a Buy at Canaccord
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

  • 25
    Jun
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

Hot Stocks
GH Research announces business updates » 07:10
03/28/22
03/28
07:10
03/28/22
07:10
GHRS

GH Research

$16.85 /

-0.01 (-0.06%)

The company said,…

The company said, "GH001 for the treatment of TRD: We plan to submit clinical trial applications in several European countries for a multi-center, randomized, controlled Phase 2b trial of GH001 in TRD in the third quarter of 2022. GH001 for the treatment of additional disorders: We have recently submitted clinical trial applications in a European country for a Phase 2a proof-of-concept clinical trial of GH001 for the treatment of patients with bipolar II disorder and a current depressive episode and for a Phase 2a proof-of-concept clinical trial of GH001 for the treatment of patients with postpartum depression. We expect to submit further clinical trial applications for these trials in additional European countries. Pending regulatory clearance, we expect to initiate these trials in the third quarter of 2022. GH001 in healthy volunteers: We now have the final safety results of our Phase 1 clinical pharmacology trial in healthy volunteers and the data continue to support the safety profile of GH001 single doses and the proprietary GH001 IDR. Results from pharmacokinetic analyses were aligned with the ultra-rapid onset and short duration of observed psychoactive effects. Results of cognitive function tests as well as psychoactive effect assessments were aligned with results of previous trials. The full results of the trial support that an interval down to 1 hour between individual doses of the IDR is feasible for use in future clinical trials. Other GH001 regulatory interactions: We have recently submitted a request for a pre-IND meeting with the FDA to discuss our planned filing of a U.S. IND for GH001 in TRD. The meeting has been granted by the FDA for the second quarter of 2022. The proposed IND-opening study is a Phase 1 imaging study in patients with TRD designed to further elucidate the mechanism of action of GH001. There are no current plans for additional regulatory meetings with other agencies. Intellectual property: We have recently filed a number of new patent applications, which have not yet been published, that relate to further aspects of 5-MeO-DMT use in a therapeutic context, including novel manufacturing methods of 5-MeO-DMT, novel salt forms of 5-MeO-DMT and novel uses of 5-MeO-DMT."

ShowHide Related Items >><<
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

GHRS GH Research
$16.85 /

-0.01 (-0.06%)

12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
07/20/21 Canaccord
GH Research initiated with a Buy at Canaccord
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

  • 25
    Jun
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

Earnings
GH Research reports 2021 EPS (21.1c), consensus (31c) » 07:09
03/28/22
03/28
07:09
03/28/22
07:09
GHRS

GH Research

$16.85 /

-0.01 (-0.06%)

The company said,…

The company said, "In December 2021, we reported the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001, our proprietary inhalable 5-methoxy-N,N-dimethyltryptamine product candidate, in patients with treatment-resistant depression. The primary endpoint of the Phase 2 part of the trial was met with 7 of 8 patients in remission at day 7 after dosing. Patients followed a proprietary individualized dosing regimen with up to three increasing GH001 doses on a single day. No serious and no severe adverse events, no clinically significant changes in any of the safety laboratory analyses, vital signs, psychiatric safety assessments or measures of cognitive function and no signal for suicidal ideation or behavior were observed. Furthermore, we reported positive preliminary safety results from a Phase 1 clinical pharmacology trial in healthy volunteers, which supported the safety profile of GH001 single doses and the proprietary GH001 IDR with up to three increasing GH001 doses on a single day, given in two dose intervals."

ShowHide Related Items >><<
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

GHRS GH Research
$16.85 /

-0.01 (-0.06%)

12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
07/20/21 Canaccord
GH Research initiated with a Buy at Canaccord
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

  • 25
    Jun
GHRS GH Research
$16.85 /

-0.01 (-0.06%)

Hot Stocks
GH Research PLC trading resumes  10:24
02/25/22
02/25
10:24
02/25/22
10:24
GHRS

GH Research

$16.39 /

+ (+0.00%)

 
ShowHide Related Items >><<
GHRS GH Research
$16.39 /

+ (+0.00%)

GHRS GH Research
$16.39 /

+ (+0.00%)

12/07/21 Canaccord
GH Research price target raised to $45 from $35 at Canaccord
07/20/21
Fly Intel: Top five analyst initiations
07/20/21 Cowen
GH Research initiated with an Outperform at Cowen
07/20/21 Canaccord
GH Research initiated with a Buy at Canaccord
GHRS GH Research
$16.39 /

+ (+0.00%)

  • 25
    Jun
GHRS GH Research
$16.39 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.